Similarly, Tregs primarily foster disease progression and lymph node metastasis in various tumors by suppressing immune responses, and their presence in PTC is linked to more aggressive disease states.[26,27] Mechanistically, tumors downregulate CD4+ and CD8+ effector T lymphocytes by enhancing the activity of FOXP3+ Tregs, thus facilitating immune evasion.[28] The proportion of CD4+ CD25+ CD127low/‐ Tregs within CD4+ T cells is substantially increased in PTC patients compared to those with multinodular goiter (MNG). This evidence concerns the gene FOXP3 and multinodular goiter.